Skip to content

Ketamine: all studies

Page 26 of 449: studies 251 to 260 of 4,486, newest first. Back to the ketamine overview

Research

Ketamine for the Treatment of Obsessive-Compulsive Disorder (OCD): A Systematic Review on Efficacy and Tolerability.

Clinical Neuropharmacology June 19, 2026 Isabela Heroiu, Gia Han Le, Maria‐christina Sioufi et al.

This systematic review aims to assess the efficacy and tolerability of ketamine in the treatment of obsessive-compulsive disorder. Obsessive-compulsive disorder is a chronic and severe disorder characterized by intrusive thoughts and repetitive behaviours that can cause significant distress. Notwithstanding current treatments and interventions for obsessive-compulsive disorder, some individuals...

Ketamine-assisted psychotherapy for posttraumatic stress disorder: a systematic review and individual participant data meta-analysis of predictors of treatment effects.

Psychotherapy and Psychosomatics June 19, 2026 Judith Rohde, Tyler M Moore, Kathryn Walker et al.

Ketamine combined with psychotherapy has shown promise in treating posttraumatic stress disorder (PTSD), but predictors of clinical benefit remain unclear. In this systematic review and individual participant data meta-analysis (IPDMA), we examined patient- and treatment-level predictors of PTSD symptom change after combined treatment. Eligible studies combined ketamine with psychotherapy in...

At-Home Telehealth-Supported Subcutaneous Ketamine Therapy in Adults With Moderate to Severe Depression, Anxiety, or PTSD: A Real-World Observational Study of Safety, Feasibility, and Clinical Outcomes in a Large, Heterogeneous Cohort in the United States.

Journal of Medical Internet Research June 17, 2026 Acacia C Parks, Amanda L Woodward, Robert D Henry et al.

Background: Depression, anxiety,, and PTSD are leading global causes of disability. Standard interventions utilize slow mechanisms of action, high attrition, and significant accessibility barriers. While intravenous (IV) and intranasal ketamine are rapid-acting alternatives, high cost and intensive logistical requirements limit adoption. Sublingual (SL) at-home ketamine addresses some gaps but...

Prophylactic efficacy of cannabidiol and sodium nitroprusside in a ketamine model of schizophrenia: sex-dependent effects on positive-like and cognitive impairments

Brazilian Journal of Psychiatry June 16, 2026 Daniel B.a. Prado, Matheus T. Rossignoli, Rafael N. Ruggiero et al.

Objective: Current treatments for schizophrenia (SZ) are often not effective for all symptoms, with sex-dependent effects poorly understood. Cannabidiol (CBD) and sodium nitroprusside (SNP) have emerged as potential prophylactic options. We evaluated their efficacy in preventing positive, negative, and cognitive deficits in a ketamine (KET) rodent model of SZ in both sexes. Methods: Wistar rats...

Burnout Symptom Outcomes During At-Home Ketamine-Assisted Therapy: A Real-World Retrospective Analysis of 395 Adults

Research Square June 16, 2026 Jack Swain, Davis Carter, Leonardo Vando et al. preprint

Abstract Background Occupational burnout, recognized in ICD-11 as an occupational phenomenon, is a syndrome of chronic workplace stress comprising emotional exhaustion, cynicism (the analogue of the depersonalization dimension on the MBI-Human Services Survey form), and reduced professional efficacy on the Maslach Burnout Inventory-General Survey (MBI-GS). Burnout is common among US working...

Increased brain VDAC1 protein levels correlate with behavioural performance in a ketamine murine model of schizophrenia and are attenuated by the mGluR2 modulator JNJ-46356479.

Schizophrenia Research June 16, 2026 David Olivares-Berjaga, Natàlia Rodríguez, Albert Martínez-pinteño et al.

Schizophrenia (SZ) is a neurodevelopmental disorder involving excitatory/inhibitory imbalance and apoptotic dysregulation. VDAC1, a voltage-dependent anion channel protein located in the mitochondrial outer membrane, plays a pivotal role in mitochondria-mediated apoptosis. However, its involvement in SZ remains underexplored. This study aimed to investigate VDAC1 protein levels in the...

Modulation of early non-rapid eye movement slow wave activity by ketamine in treatment-resistant depression.

Neuropsychopharmacology June 16, 2026 Nadia S. Hejazi, Mina Kheirkhah, Brady A. Riedner et al.

Slow-wave activity (SWA), a key indicator of sleep homeostasis, is often diminished in individuals with treatment-resistant depression (TRD). Ketamine, a rapid-acting antidepressant, increases SWA during the first period of non-rapid eye movement (NREM1) sleep. However, research into how ketamine affects sleep and its connection to treatment outcomes in TRD has been limited by small sample...

KETAMINE IN THE TREATMENT OF DEPRESSION - A REVIEW ARTICLE

International Journal of Innovative Technologies in Social Science June 15, 2026 Olga Szeidl, Joanna Mikołajczyk, Artur Hawajski et al.

Background: Depression is a multifactorial disorder involving neurotransmitter dysregulation, HPA axis hyperactivity, neuroinflammation, and impaired neuroplasticity. While combination psychotherapy and pharmacotherapy remains first-line, ~30% of patients develop TRD. In the last few years ketamine has emerged as a rapid-acting therapeutic option for treatment-resistant cases. Aim: To review...

THE PSYCHEDELIC AND KETAMINE RENAISSANCE IN THE FACE OF THE CRISIS IN MODERN PSYCHIATRY

International Journal of Innovative Technologies in Social Science June 15, 2026 Julia Osipowska, Marlena Kwolek, Alicja Judzińska et al.

Introduction: Contemporary psychiatry is grappling with a profound stagnation in innovation. It is primarily relying on the chronic management of symptoms through traditional daily-dose pharmacotherapy. The emergence of psychedelics and ketamine marks a significant departure from this model. It is offering rapid-acting, interventional alternatives that target the underlying neurobiological...

DOI: 10.31435/ijitss.2(50).2026.5605 (opens in new tab) Multidisciplinary approach Bioethics Face sociological concept Licensure +4

Acute pretrauma ethanol exacerbates PTSD-like phenotype in rats and is reversed by early intranasal ketamine

Scientific Reports June 14, 2026 Bar Eilat Yogev, Gal Levi, Noa Efroni et al.

Alcohol consumption before trauma is a prevalent but understudied risk factor for posttraumatic stress disorder (PTSD). This study investigated whether acute ethanol exposure prior to trauma modulates PTSD-like symptom development in rats, identified hippocampal mechanisms involved, and tested an early post-trauma intervention. Adult male Sprague-Dawley rats received ethanol (1.6 g/kg, 40% v/v,...